Results 141 to 150 of about 24,744 (229)

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1304-1309, August 2026.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” [PDF]

Clinical and Molecular Hepatology
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan   +2 more
doaj   +1 more source

Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy. [PDF]

Cureus
Mahapatra H, Gupta PK, Paul A, Nampalliwar A, Bansal M, Das B, Namboothiri KP.   +6 more
europepmc   +1 more source

Monocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1335-1347, August 2026.
This study examined whether dipeptidyl peptidase 4 (DPP4) characteristics in peripheral blood monocytes relate to renal parameters. Monocyte DPP4 activity was independently associated with urinary albumin excretion in patients with type 2 diabetes, suggesting that monocytes may function as a cellular link between DPP4 and diabetic kidney disease ...
Hideyuki Okuma, Takahiro Tsutsumi, Kyoichiro Tsuchiya   +2 more
wiley   +1 more source

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset. [PDF]

NPJ Parkinsons Dis
Vincze K, Szwajda A, Ploner A, Karlsson R, Kang X, Tang B, Qin C, Domenighetti C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, Portugal B, May P, Bobbili DR, Radivojkov-Blagojevic M, Lichtner P, Singleton AB, Hernandez DG, Edsall C, Mellick GD, Zimprich A, Pirker W, Rogaeva E, Lang AE, Koks S, Taba P, Lesage S, Brice A, Corvol JC, Chartier-Harlin MC, Mutez E, Brockmann K, Deutschlander AB, Burbulla LF, Hadjigeorgiou GM, Dardiotis E, Stefanis L, Simitsi AM, Valente EM, Petrucci S, Straniero L, Zecchinelli A, Pezzoli G, Brighina L, Ferrarese C, Annesi G, Quattrone A, Gagliardi M, Matsuo H, Nakayama A, Hattori N, Nishioka K, Chung SJ, Kim YJ, Kolber P, Van de Warrenburg BP, Bloem BR, Toft M, Pihlstrøm L, Correia Guedes L, Ferreira JJ, Bardien S, Carr J, Tolosa E, Ezquerra M, Pastor P, Ran C, Belin AC, Puschmann A, Clarke CE, Morrison KE, Tan M, Krainc D, Farrer MJ, Landoulsi Z, Kruger R, Gasser T, Elbaz A, Sharma M, Pedersen NL, Carlsson S, Hägg S, Wirdefeldt K, Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson’s Disease (COURAGE-PD) Consortium, Domenighetti C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, Portugal B, May P, Bobbili DR, Radivojkov-Blagojevic M, Lichtner P, Singleton AB, Hernandez DG, Edsall C, Mellick GD, Zimprich A, Pirker W, Rogaeva E, Lang AE, Koks S, Taba P, Lesage S, Brice A, Corvol JC, Chartier-Harlin MC, Mutez E, Brockmann K, Deutschlander AB, Burbulla LF, Hadjigeorgiou GM, Dardiotis E, Stefanis L, Simitsi AM, Valente EM, Petrucci S, Straniero L, Zecchinelli A, Pezzoli G, Brighina L, Ferrarese C, Annesi G, Quattrone A, Gagliardi M, Matsuo H, Nakayama A, Hattori N, Nishioka K, Chung SJ, Kim YJ, Kolber P, Van de Warrenburg BP, Bloem BR, Toft M, Pihlstrøm L, Correia Guedes L, Ferreira JJ, Bardien S, Carr J, Tolosa E, Ezquerra M, Pastor P, Ran C, Belin AC, Puschmann A, Clarke CE, Morrison KE, Tan M, Krainc D, Farrer MJ, Landoulsi Z, Kruger R, Gasser T, Elbaz A, Sharma M, Wirdefeldt K.   +156 more
europepmc   +1 more source

Exploration of Glitazone/Thiazolidinedione Derivatives: Molecular Design and Therapeutic Potential. [PDF]

Bioengineering (Basel)
Salahuddin, Mazumder A, Ahsan MJ, Kumar R, Ullah Z, Shahar Yar M, Shabana K.   +6 more
europepmc   +1 more source

Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. [PDF]

World J Diabetes
An XD, Duan LY, Zhang YH, Jia QY, Zhang YM, Qiao Y.   +5 more
europepmc   +1 more source

PPARγ: a key orchestrator of epidermal barrier, immune responses, and lipid metabolism in atopic dermatitis pathogenesis and therapy. [PDF]

Front Allergy
Bao Y, Xu K, Du Y, Feng M, Li L, Li L, Yan G, Li X.   +7 more
europepmc   +1 more source

Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data. [PDF]

J Cachexia Sarcopenia Muscle
Ueta S, Niimura T, Goda M, Ishida T, Iwata N, Takeda T, Kawada K, Miyata K, Aizawa F, Yagi K, Hamano H, Chuma M, Izawa-Ishizawa Y, Zamami Y, Ishizawa K.   +14 more
europepmc   +1 more source

Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis. [PDF]

Curr Diab Rep
Raptis D, Chiotis S, Papamichalis T, Bekiari E, Tsapas A, Karagiannis T.   +5 more
europepmc   +1 more source